Last reviewed · How we verify

5LGr

Tasly Pharmaceuticals, Inc. · Phase 3 active Small molecule

5LGr is a small molecule drug that targets the SGLT2 receptor.

5LGr is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name5LGr
Also known asWuling Granule
SponsorTasly Pharmaceuticals, Inc.
Drug classSGLT2 inhibitor
TargetSGLT2
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

By inhibiting SGLT2, 5LGr reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results